# MediWound (MDWD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MDWD
## Company Profile
- Ticker: MDWD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel
## Stock Data
- Close: 13.29 USD
- Market cap: 176847028.8 USD
- Last updated: 2026-09-04
## Business Overview
### Enzymatic Tissue Repair Company
MediWound develops non-surgical enzymatic therapies for tissue repair. Its approved product NexoBrid is used for enzymatic removal of burn eschar and is commercialized in the United States, European Union, Japan, and other international markets.
### NexoBrid Commercial Foundation
NexoBrid is an approved enzymatic debridement product with established use in specialized burn care. Regional commercialization through partners gives MediWound product revenue and market access while the company continues investing in broader supply capacity.
### Emergency Preparedness Role
NexoBrid also has strategic applications in national preparedness and military medicine. A BARDA-supported contract with Vericel covers procurement, inventory management, potential blast-trauma development, and next-generation manufacturing capacity.
### EscharEx Chronic Wound Pipeline
EscharEx is a late-stage enzymatic debridement candidate for chronic wounds, including venous leg ulcers, diabetic foot ulcers, and pressure ulcers. MediWound is positioning it as a potential next-generation standard for chronic wound debridement.
### Manufacturing and Supply Expansion
MediWound is expanding NexoBrid production capacity to support commercial demand and strategic stockpiling. Regulatory qualification of the enlarged facility is important to the company’s ability to supply additional markets and government preparedness programs.
## Why The Stock Is Moving

As of Sep 4, 2026, MDWD closed up 0.61% at $13.29. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of an investigator-sponsored EscharEx study in pressure ulcers in the fourth quarter of 2026.
- Interim sample-size assessment and completion of enrollment in the Phase 3 VALUE study by the end of the first quarter of 2027.

## Recent News
- 2026-09-02 11:00 EST — [MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/MDWD/mediwound-to-present-at-the-h-c-wainwright-28th-annual-global-investment-confere-f4c810ab) — Source: MediWound
- 2026-08-13 11:00 EST — [MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MDWD/mediwound-reports-second-quarter-2026-financial-results-and-provides-corporate-u-5b3d2b7e) — Source: MediWound
- 2026-07-29 12:00 EST — [MediWound to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MDWD/mediwound-to-report-second-quarter-2026-financial-results-11b5e0a5) — Source: MediWound
- 2026-05-27 11:00 EST — [MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/MDWD/mediwound-reports-first-quarter-2026-financial-results-and-provides-corporate-up-d4323a9b) — Source: MediWound
- 2026-05-07 12:00 EST — [MediWound to Report First Quarter 2026 Financial Results](https://biopharmsignal.com/news/MDWD/mediwound-to-report-first-quarter-2026-financial-results-6c090220) — Source: MediWound